---
title: "Insulet Corporation (PODD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PODD.US.md"
symbol: "PODD.US"
name: "Insulet Corporation"
industry: "Health Care Equipment"
datetime: "2026-05-20T06:51:43.137Z"
locales:
  - [en](https://longbridge.com/en/quote/PODD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PODD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PODD.US.md)
---

# Insulet Corporation (PODD.US)

## Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.insulet.com](https://www.insulet.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.31)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 15 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 31.92% |  |
| Net Profit YoY | -24.71% |  |
| P/B Ratio | 8.11 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10562170138.26 |  |
| Revenue | 2900800000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 23.00% | A |
| Profit Margin | 10.44% | B |
| Gross Margin | 69.45% | A |
| Revenue YoY | 31.92% | A |
| Net Profit YoY | -24.71% | D |
| Total Assets YoY | -15.07% | E |
| Net Assets YoY | -2.11% | D |
| Cash Flow Margin | 204.52% | B |
| OCF YoY | 31.92% | A |
| Turnover | 0.89 | B |
| Gearing Ratio | 56.39% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Insulet Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "31.92%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.71%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.11",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10562170138.26",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2900800000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "23.00%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "10.44%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "69.45%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "31.92%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.71%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.07%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-2.11%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "204.52%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "31.92%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.89",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "56.39%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 35.37 | 32/183 | 94.15 | 71.79 | 53.30 |
| PB | 8.22 | 117/183 | 16.11 | 15.03 | 11.17 |
| PS (TTM) | 3.69 | 82/183 | 9.74 | 9.07 | 6.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **25**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 17 | 68% |
| Overweight | 4 | 16% |
| Hold | 3 | 12% |
| Underweight | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 154.61 |
| Highest Target | 435.00 |
| Lowest Target | 220.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PODD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PODD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PODD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PODD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**